Video

Dr. Tap on the Effects of the COVID-19 Pandemic on Sarcoma

William D. Tap, MD, discusses the effects of the COVID-19 pandemic on the treatment of patients with sarcoma.

William D. Tap, MD, chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses the effects of the COVID-19 pandemic on the treatment of patients with sarcoma.

The treatment of patients with sarcoma was significantly affected by the COVID-19 pandemic, says Tap. Questions that arose during the height of the pandemic included how to appropriately continue patient care, how patients with cancer are affected by COVID-19, how to safely and remotely manage patients with cancer, and how to continue clinical research safely, Tap explains. Additionally, investigators in the field of sarcoma are trying to understand how COVID-19 affects patients based on the different types of treatments they receive, including chemotherapies, alkylating agents, anthracyclines, and targeted therapies, Tap adds.

Ultimately, these questions remain less understood in sarcoma compared with other more common tumor types, Tap says. The hope is that enough data will be available from patients with sarcoma to draw conclusions about how the COVID-19 pandemic affected this patient population, concludes Tap.

Related Videos
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD